Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for AKRO

Stock NameAkero Therapeutics Inc
TickerAKRO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS00973Y1082
LEI549300SI3KG74LBE2955

Show aggregate AKRO holdings

News associated with AKRO

Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $81.57 Average Target Price from Analysts
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued ratings on the stock in […] - 2025-09-05 02:52:56
Akero Therapeutics (NASDAQ:AKRO) Research Coverage Started at TD Cowen
TD Cowen assumed coverage on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note published on Monday morning, MarketBeat reports. The brokerage issued a buy rating and a $76.00 target price on the stock. AKRO has been the subject of several other research reports. Citigroup dropped their price target on shares of […] - 2025-08-07 02:54:52
Universal Beteiligungs und Servicegesellschaft mbH Invests $463,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,436 shares of the company’s stock, valued at approximately $463,000. A number of other […] - 2025-08-04 05:14:50
KLP Kapitalforvaltning AS Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
KLP Kapitalforvaltning AS decreased its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 12.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,600 shares of the company’s stock after selling 1,400 shares during the […] - 2025-07-31 05:14:49
Jennison Associates LLC Purchases Shares of 13,178 Akero Therapeutics, Inc. (NASDAQ:AKRO)
Jennison Associates LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 13,178 shares of the company’s stock, valued at approximately $533,000. Several other institutional investors and hedge funds have also […] - 2025-07-23 06:20:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Bank of New York Mellon Corp
Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,665 shares of the company’s stock after acquiring an additional 12,235 shares […] - 2025-07-22 08:19:03
Bank of New York Mellon Corp Acquires 12,235 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Bank of New York Mellon Corp raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 6.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 212,665 shares of the company’s stock after buying an additional 12,235 shares during the quarter. Bank […] - 2025-07-22 07:24:51
Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells $1,534,800.00 in Stock
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $51.16, for a total value of $1,534,800.00. Following the sale, the chief executive officer directly owned 520,757 shares of the company’s […] - 2025-07-14 06:16:53
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of “Buy” by Brokerages
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has received a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last […] - 2025-07-14 05:38:47
Mirae Asset Global Investments Co. Ltd. Purchases 338 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Mirae Asset Global Investments Co. Ltd. grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 14.5% during the first quarter, HoldingsChannel reports. The firm owned 2,664 shares of the company’s stock after buying an additional 338 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Akero Therapeutics were worth […] - 2025-07-07 04:41:41
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.50 Average Target Price from Analysts
Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have been assigned a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-06-24 03:11:00
Millennium Management LLC Sells 57,892 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)
Millennium Management LLC decreased its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 77.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 16,736 shares of the company’s stock after selling 57,892 shares during the period. Millennium Management LLC’s holdings in Akero Therapeutics […] - 2025-06-10 05:18:54
Akero Therapeutics Sees Unusually High Options Volume (NASDAQ:AKRO)
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 3,105 call options on the company. This represents an increase of approximately 106% compared to the average volume of 1,508 call options. Insider Activity In other news, insider Timothy Rolph sold 12,500 shares of […] - 2025-06-10 02:00:51
Akero Therapeutics (NASDAQ:AKRO) Given New $64.00 Price Target at Bank of America
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price raised by Bank of America from $63.00 to $64.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Other research analysts also recently issued research reports about the company. Citigroup reduced their price target on Akero Therapeutics […] - 2025-05-28 02:44:51
ProShare Advisors LLC Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
ProShare Advisors LLC boosted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 32.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 22,398 shares of the company’s stock after acquiring an additional 5,477 shares during the period. ProShare Advisors LLC’s holdings in Akero Therapeutics were worth $623,000 as of […] - 2025-05-26 05:16:50
Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $78.00 by Analysts at Citigroup
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective decreased by Citigroup from $80.00 to $78.00 in a research note issued to investors on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other analysts have also weighed in on AKRO. HC Wainwright raised their price objective on shares of Akero […] - 2025-05-14 04:58:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Average Price Target from Analysts
Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have issued ratings on the stock […] - 2025-05-05 04:28:56
Sterling Capital Management LLC Boosts Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Sterling Capital Management LLC lifted its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 764.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,789 shares of the company’s stock after purchasing an additional 1,582 shares during the period. Sterling Capital Management LLC’s holdings in Akero […] - 2025-04-24 05:56:54
Vanguard Group Inc. Has $103.06 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Vanguard Group Inc. raised its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 0.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 3,704,411 shares of the company’s stock after purchasing an additional 27,830 shares during the period. Vanguard Group Inc. owned approximately […] - 2025-04-10 04:38:50
KLP Kapitalforvaltning AS Invests $306,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)
KLP Kapitalforvaltning AS acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 11,000 shares of the company’s stock, valued at approximately $306,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of AKRO. Handelsbanken […] - 2025-04-07 05:06:49
Akero Therapeutics (NASDAQ:AKRO) and Rezolute (NASDAQ:RZLT) Head to Head Comparison
Rezolute (NASDAQ:RZLT – Get Free Report) and Akero Therapeutics (NASDAQ:AKRO – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Analyst Ratings This is a breakdown of recent ratings […] - 2025-03-26 04:10:42
Y Intercept Hong Kong Ltd Lowers Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)
Y Intercept Hong Kong Ltd lessened its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 47.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,950 shares of the company’s stock after selling 7,966 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Akero Therapeutics were worth $249,000 at […] - 2025-03-05 07:07:16
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $75.00
Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price boosted by HC Wainwright from $72.00 to $75.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. AKRO has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Akero […] - 2025-03-04 04:50:49
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Decreased by Global Retirement Partners LLC
Global Retirement Partners LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) by 13.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,917 shares of the company’s stock after selling 740 shares during the period. Global […] - 2025-02-27 06:52:59
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $75.86 Consensus Target Price from Analysts
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last […] - 2025-02-19 05:06:50
Technology Stocks Upended by China’s DeepSeek
The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini S&P futures (ESH25 ) are down by -1.38%, and March E-mini Nasdaq... - 2025-01-28 13:04:47
Stocks Hit by AI Jitters
The S&P 500 Index ($SPX ) (SPY ) today is down -1.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.68%. March E-mini S&P futures (ESH25 ) are down sharply by -1.70%, and March E-mini... - 2025-01-28 02:53:37

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) AKRO holdings

DateNumber of AKRO Shares HeldBase Market Value of AKRO SharesLocal Market Value of AKRO SharesChange in AKRO Shares HeldChange in AKRO Base ValueCurrent Price per AKRO Share HeldPrevious Price per AKRO Share Held
2025-11-11 (Tuesday)51,974USD 2,819,590AKRO holding increased by 5718USD 2,819,5900USD 5,718 USD 54.25 USD 54.14
2025-11-10 (Monday)51,974AKRO holding increased by 133USD 2,813,872AKRO holding increased by 12384USD 2,813,872133USD 12,384 USD 54.14 USD 54.04
2025-11-07 (Friday)51,841USD 2,801,488AKRO holding increased by 6740USD 2,801,4880USD 6,740 USD 54.04 USD 53.91
2025-11-06 (Thursday)51,841AKRO holding increased by 133USD 2,794,748AKRO holding decreased by -69USD 2,794,748133USD -69 USD 53.91 USD 54.05
2025-11-05 (Wednesday)51,708USD 2,794,817AKRO holding increased by 1034USD 2,794,8170USD 1,034 USD 54.05 USD 54.03
2025-11-04 (Tuesday)51,708AKRO holding increased by 133USD 2,793,783AKRO holding increased by 4091USD 2,793,783133USD 4,091 USD 54.03 USD 54.09
2025-11-03 (Monday)51,575USD 2,789,692AKRO holding decreased by -5673USD 2,789,6920USD -5,673 USD 54.09 USD 54.2
2025-10-31 (Friday)51,575USD 2,795,365AKRO holding decreased by -3095USD 2,795,3650USD -3,095 USD 54.2 USD 54.26
2025-10-30 (Thursday)51,575AKRO holding increased by 665USD 2,798,460AKRO holding increased by 49320USD 2,798,460665USD 49,320 USD 54.26 USD 54
2025-10-29 (Wednesday)50,910AKRO holding increased by 266USD 2,749,140AKRO holding increased by 14364USD 2,749,140266USD 14,364 USD 54 USD 54
2025-10-28 (Tuesday)50,644USD 2,734,776AKRO holding increased by 7597USD 2,734,7760USD 7,597 USD 54 USD 53.85
2025-10-27 (Monday)50,644USD 2,727,179AKRO holding increased by 4051USD 2,727,1790USD 4,051 USD 53.85 USD 53.77
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of AKRO by Blackrock for IE00BYXG2H39

Show aggregate share trades of AKRO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY13354.18054.025 54.041USD 7,187 44.61
2025-11-06BUY13354.10053.900 53.920USD 7,171 44.51
2025-11-04BUY13354.10054.000 54.010USD 7,183 44.41
2025-10-30BUY66554.31053.935 53.973USD 35,892 44.26
2025-10-29BUY26654.00054.070 54.063USD 14,381 44.21
2025-10-22SELL-53253.61053.920 53.889USD -28,669 43.95 Loss of -5,288 on sale
2025-10-20BUY26653.91053.950 53.946USD 14,350 43.84
2025-10-17BUY66553.84053.870 53.867USD 35,822 43.79
2025-10-15BUY1,06453.60053.900 53.870USD 57,318 43.73
2025-10-03BUY92446.10046.865 46.789USD 43,233 43.66
2025-10-02BUY13246.41046.800 46.761USD 6,172 43.65
2025-09-30BUY26447.48048.030 47.975USD 12,665 43.61
2025-09-26BUY26447.74047.820 47.812USD 12,622 43.56
2025-09-25BUY26446.22047.320 47.210USD 12,463 43.55
2025-09-24SELL-2,13847.46048.440 48.342USD -103,355 43.52 Loss of -10,300 on sale
2025-09-18BUY13846.20047.850 47.685USD 6,581 43.51
2025-09-17BUY41442.18043.125 43.031USD 17,815 43.52
2025-08-20SELL-55247.95048.460 48.409USD -26,722 43.45 Loss of -2,739 on sale
2025-07-30BUY55247.72048.745 48.642USD 26,851 43.26
2025-07-17SELL-27654.33054.990 54.924USD -15,159 42.80 Loss of -3,347 on sale
2025-07-16BUY52653.60053.820 53.798USD 28,298 42.73
2025-07-11SELL-1,08851.57052.040 51.993USD -56,568 42.54 Loss of -10,290 on sale
2025-07-07BUY40851.52052.730 52.609USD 21,464 42.29
2025-07-02BUY7,48051.88052.600 52.528USD 392,909 42.16
2025-06-20BUY1,19554.20055.000 54.920USD 65,629 42.07
2025-06-11BUY26452.95555.460 55.209USD 14,575 41.40
2025-06-10BUY26454.52054.820 54.790USD 14,465 41.30
2025-06-04SELL-13252.99053.480 53.431USD -7,053 40.91 Loss of -1,653 on sale
2025-04-23BUY13239.61040.590 40.492USD 5,345 39.96
2025-04-10SELL-1,05634.82036.530 36.359USD -38,395 40.24 Profit of 4,099 on sale
2025-04-08SELL-13234.04039.233 38.714USD -5,110 40.34 Profit of 215 on sale
2025-04-07SELL-13235.97038.820 38.535USD -5,087 40.40 Profit of 246 on sale
2025-04-04SELL-66036.73039.990 39.664USD -26,178 40.44 Profit of 511 on sale
2025-04-01BUY1,15738.64041.710 41.403USD 47,903 40.44
2025-03-31SELL-39040.48041.120 41.056USD -16,012 40.44 Loss of -240 on sale
2025-03-21BUY6,31445.22045.920 45.850USD 289,497 40.15
2025-03-14SELL-1,76044.15045.584 45.441USD -79,975 39.85 Loss of -9,845 on sale
2025-03-07SELL-21842.12043.940 43.758USD -9,539 39.56 Loss of -916 on sale
2025-03-04SELL-10944.53045.650 45.538USD -4,964 39.32 Loss of -677 on sale
2025-02-25BUY21847.47049.660 49.441USD 10,778 38.62
2025-02-19SELL-10950.67050.760 50.751USD -5,532 37.73 Loss of -1,420 on sale
2025-02-13BUY32749.23049.920 49.851USD 16,301 36.75
2025-02-12BUY10949.44050.700 50.574USD 5,513 36.49
2025-02-11BUY43649.95051.133 51.015USD 22,242 36.21
2024-12-30SELL-3,51127.96028.050 28.041USD -98,452 31.37 Profit of 11,675 on sale
2024-11-18SELL-1,78529.56029.850 29.821USD -53,230 31.52 Profit of 3,032 on sale
2024-11-08SELL-11934.45034.730 34.702USD -4,130 31.25 Loss of -411 on sale
2024-10-21SELL-11930.90031.115 31.093USD -3,700 0.00 Loss of -3,700 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of AKRO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19320,5540439,67772.9%
2025-09-18580,3188,0001,504,42038.6%
2025-09-17204,88220453,80345.1%
2025-09-16206,79620330,74562.5%
2025-09-15220,05926481,70145.7%
2025-09-12353,7940539,61965.6%
2025-09-11255,45091523,79248.8%
2025-09-10448,3407,548553,34681.0%
2025-09-09151,46214,540268,13156.5%
2025-09-08190,27026,862376,99350.5%
2025-09-05117,6830243,94448.2%
2025-09-04194,34829609,13831.9%
2025-09-03127,8543245,66252.0%
2025-09-02116,9863,904277,82742.1%
2025-08-2985,1730146,20958.3%
2025-08-28122,035238187,63865.0%
2025-08-27153,819113232,96766.0%
2025-08-2692,3044,102207,51944.5%
2025-08-2596,7060144,62366.9%
2025-08-22146,1800328,68144.5%
2025-08-2199,543200166,23359.9%
2025-08-20186,4440265,08670.3%
2025-08-19135,6200193,66870.0%
2025-08-18108,3950171,50763.2%
2025-08-15554,6635878,28963.2%
2025-08-14325,70313,249531,75361.3%
2025-08-13127,0860277,10845.9%
2025-08-12187,43230,605288,84464.9%
2025-08-11293,88313,502490,12360.0%
2025-08-08199,0640355,71956.0%
2025-08-07275,5290721,33938.2%
2025-08-06963,4382111,390,49269.3%
2025-08-05318,6384,289433,70373.5%
2025-08-04238,39792375,44263.5%
2025-08-01223,655714301,11874.3%
2025-07-31224,46697335,69166.9%
2025-07-30131,3290227,51257.7%
2025-07-2999,36849195,57550.8%
2025-07-28169,5887309,20654.8%
2025-07-2592,23160188,78448.9%
2025-07-2479,79165200,04439.9%
2025-07-23133,90177303,68744.1%
2025-07-2282,61650289,83328.5%
2025-07-2189,737216210,90142.5%
2025-07-1895,387211239,96839.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.